• (-)-p-Bromotetramisole Oxalate br Acknowledgments and Disclo

  2024-07-12

  

  Acknowledgments and Disclosures Introduction Over the last decade, the most visible strategy for the treatment of Alzheimer's disease (AD) has been amyloid β peptide (Aβ) immunotherapy (reviewed in [1]). Although the first efforts with Aβ immunotherapy failed to complete clinical trials [1], A

• br AMPK as a druggable target AMPK signaling has

  2024-07-12

  

  AMPK as a druggable target AMPK signaling has attracted considerable attention within the past decades, owing to the capacity of pharmacological compounds (e.g., 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR] and metformin) or natural compounds (e.g., resveratrol) to activate AMPK in

• Cinacalcet HCl br Results br Discussion By using an unbiased

  2024-07-12

  

  Results Discussion By using an unbiased proteomic screen for xCT binding partners, followed by functional validation, we have made the surprising discovery that mTORC2 regulates amino Cinacalcet HCl metabolism in tumor cells by phosphorylating serine 26 of the cystine-glutamate antiporter xCT

• Interestingly intermittent high doses of AKT

  2024-07-12

  

  Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula

• br Detection and possible treatments for prostate cancer

  2024-07-12

  

  Detection and possible treatments for prostate cancer PC can be diagnosed, by screening for prostate-specific antigen (PSA) and after diagnosis, treatments may include intense observation, radical prostatectomy, radiation, chemotherapy, hormone therapy or vaccination depending on the type and sta

• br Hyperadiponectinemia in disease conditions Other evidence

  2024-07-12

  

  Hyperadiponectinemia in disease conditions Other evidence indicates that hyperadiponectinemia does not necessarily always imply a healthy outcome. Indeed, a recent study suggested that hyperadiponectinemia occurs in various diseases. Given that the risk for AD and vascular dementia is increased i

• br Introduction Nausea and vomiting are among the most distr

  2024-07-12

  

  Introduction Nausea and vomiting are among the most distressing side effects associated with chemotherapy in cancer patients (Billio et al., 2010). Severe emesis can negatively affect a patient's nutritional state, ability to work and motivation, which can, in turn, interfere with the clinical co

• Introduction Adenosine monophosphate cAMP is a general

  2024-07-12

  

  Introduction Adenosine 3′,5′-monophosphate (cAMP) is a general-purpose signaling molecule present in most branches of life. Intracellular cAMP levels control diverse cellular functions. In bacteria, cAMP regulates metabolism by activation of the catabolite activator protein (CAP), also known as cAM

• Phosphodiesterase inhibition increases the intracellular lev

  2024-07-12

  

  Phosphodiesterase inhibition increases the intracellular levels of cAMP to restore spontaneous contraction (Essayan, 2001, Qi and Kwan, 1996), acting downstream of adenylyl cyclase. Therefore, cardiac arrest induced by decreased intracellular cAMP levels could be reversed by phosphodiesterase inhibi

• If overexpression of ADK is sufficient to induce spontaneous

  2024-07-12

  

  If overexpression of ADK is sufficient to induce spontaneous seizures, then reduction of ADK in engineered mice should prevent epileptogenesis. The generation of mice with moderately reduced levels of ADK in brain rather than complete ADK deficiency seems to be essential, since several lines of evi

• Direct inhibition of LO activity by BRP is

  2024-07-11

  

  Direct inhibition of 5-LO activity by BRP-187 is clearly evident in cell-free assays using PMNL homogenates and isolated human recombinant 5-LO as enzyme source. In such assays, pure FLAP inhibitors like MK886 are inactive [9], [10], [29], [44]. Wash-out experiments and studies using the nonionic de

• br Funding br Introduction l Dihydroxyphenylalanine l DOPA i

  2024-07-11

  

  Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side

• A contribution of V ATPase subunits specifically to

  2024-07-11

  

  A contribution of V-ATPase subunits specifically to phagosome-lysosome fusion was uncovered by Peri and Nüsslein-Volhard who described that depletion of the VO subunit a1 in zebrafish interferes with phagosome maturation in microglial SMIP004 sale (Peri and Nusslein-Volhard, 2008). However, loss of

• br Conclusion br Acknowledgement This

  2024-07-11

  

  Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Stroke is the leading cause of disability and the fifth leading cause of death in the United States (Writing Group et al., 2016). On average, every 4 min a human dies of stroke (Lackland et al., 2

• Two critical determinants of receptor trafficking are found

  2024-07-11

  

  Two critical determinants of receptor trafficking are found within the GABAB1 cytoplasmic tail: the di-leucine internalization signal (EKSRLL) (Margeta-Mitrovic et al., 2000, Restituito et al., 2005) and the ER retention signal (RSRR) (Calver et al., 2001, Margeta-Mitrovic et al., 2000, Pagano et al

12776 records 91/852 page Previous Next First page 上5页 9192939495 下5页 Last page